Abstract
Experience of application of preparation Gemzar as a chemotherapy agent for ductal pancreatic adenocarcinoma was analysed. In 28 patients (main group) chemotherapy using Gemzar preparation was conducted, in 30 patients (control group) chemotherapy was not conducted. The trustworthy differences of life span in patients with unresectable tumors in the main and control groups were noted. Difference of the patients life span after performance of radical pancreatic resection was not trustworthy.
Publication types
-
Clinical Trial
-
English Abstract
MeSH terms
-
Antimetabolites, Antineoplastic / administration & dosage
-
Antimetabolites, Antineoplastic / therapeutic use*
-
Carcinoma, Pancreatic Ductal / drug therapy*
-
Carcinoma, Pancreatic Ductal / mortality
-
Carcinoma, Pancreatic Ductal / surgery
-
Deoxycytidine / administration & dosage
-
Deoxycytidine / analogs & derivatives*
-
Deoxycytidine / therapeutic use
-
Disease-Free Survival
-
Gemcitabine
-
Humans
-
Pancreatic Neoplasms / drug therapy*
-
Pancreatic Neoplasms / mortality
-
Pancreatic Neoplasms / surgery
-
Treatment Outcome
Substances
-
Antimetabolites, Antineoplastic
-
Deoxycytidine
-
Gemcitabine